These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 20961433)

  • 21. Vaccine platforms for the prevention of Lassa fever.
    Purushotham J; Lambe T; Gilbert SC
    Immunol Lett; 2019 Nov; 215():1-11. PubMed ID: 31026485
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protection From Lethal Lassa Disease Can Be Achieved Both Before and After Virus Exposure by Administration of Single-Cycle Replicating Lassa Virus Replicon Particles.
    Kainulainen MH; Spengler JR; Welch SR; Coleman-McCray JD; Harmon JR; Scholte FEM; Goldsmith CS; Nichol ST; Albariño CG; Spiropoulou CF
    J Infect Dis; 2019 Sep; 220(8):1281-1289. PubMed ID: 31152662
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins.
    Bredenbeek PJ; Molenkamp R; Spaan WJ; Deubel V; Marianneau P; Salvato MS; Moshkoff D; Zapata J; Tikhonov I; Patterson J; Carrion R; Ticer A; Brasky K; Lukashevich IS
    Virology; 2006 Feb; 345(2):299-304. PubMed ID: 16412488
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lassa Virus Vaccine Candidate ML29 Generates Truncated Viral RNAs Which Contribute to Interfering Activity and Attenuation.
    Johnson DM; Cubitt B; Pfeffer TL; de la Torre JC; Lukashevich IS
    Viruses; 2021 Jan; 13(2):. PubMed ID: 33573250
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oxidation-sensitive polymersomes as vaccine nanocarriers enhance humoral responses against Lassa virus envelope glycoprotein.
    Galan-Navarro C; Rincon-Restrepo M; Zimmer G; Ollmann Saphire E; Hubbell JA; Hirosue S; Swartz MA; Kunz S
    Virology; 2017 Dec; 512():161-171. PubMed ID: 28963882
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs.
    Jiang X; Dalebout TJ; Bredenbeek PJ; Carrion R; Brasky K; Patterson J; Goicochea M; Bryant J; Salvato MS; Lukashevich IS
    Vaccine; 2011 Feb; 29(6):1248-57. PubMed ID: 21145373
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emerging trends in Lassa fever: redefining the role of immunoglobulin M and inflammation in diagnosing acute infection.
    Branco LM; Grove JN; Boisen ML; Shaffer JG; Goba A; Fullah M; Momoh M; Grant DS; Garry RF
    Virol J; 2011 Oct; 8():478. PubMed ID: 22023795
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advanced vaccine candidates for Lassa fever.
    Lukashevich IS
    Viruses; 2012 Oct; 4(11):2514-57. PubMed ID: 23202493
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Routine and pulse vaccination for Lassa virus could reduce high levels of endemic disease: A mathematical modelling study.
    Davies J; Lokuge K; Glass K
    Vaccine; 2019 Jun; 37(26):3451-3456. PubMed ID: 31088745
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bacterial-based systems for expression and purification of recombinant Lassa virus proteins of immunological relevance.
    Branco LM; Matschiner A; Fair JN; Goba A; Sampey DB; Ferro PJ; Cashman KA; Schoepp RJ; Tesh RB; Bausch DG; Garry RF; Guttieri MC
    Virol J; 2008 Jun; 5():74. PubMed ID: 18538016
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccines inducing immunity to Lassa virus glycoprotein and nucleoprotein protect macaques after a single shot.
    Mateo M; Reynard S; Carnec X; Journeaux A; Baillet N; Schaeffer J; Picard C; Legras-Lachuer C; Allan R; Perthame E; Hillion KH; Pietrosemoli N; Dillies MA; Barrot L; Vallve A; Barron S; Fellmann L; Gaillard JC; Armengaud J; Carbonnelle C; Raoul H; Tangy F; Baize S
    Sci Transl Med; 2019 Oct; 11(512):. PubMed ID: 31578242
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits.
    Robinson JE; Hastie KM; Cross RW; Yenni RE; Elliott DH; Rouelle JA; Kannadka CB; Smira AA; Garry CE; Bradley BT; Yu H; Shaffer JG; Boisen ML; Hartnett JN; Zandonatti MA; Rowland MM; Heinrich ML; Martínez-Sobrido L; Cheng B; de la Torre JC; Andersen KG; Goba A; Momoh M; Fullah M; Gbakie M; Kanneh L; Koroma VJ; Fonnie R; Jalloh SC; Kargbo B; Vandi MA; Gbetuwa M; Ikponmwosa O; Asogun DA; Okokhere PO; Follarin OA; Schieffelin JS; Pitts KR; Geisbert JB; Kulakoski PC; Wilson RB; Happi CT; Sabeti PC; Gevao SM; Khan SH; Grant DS; Geisbert TW; Saphire EO; Branco LM; Garry RF
    Nat Commun; 2016 May; 7():11544. PubMed ID: 27161536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibodies from Sierra Leonean and Nigerian Lassa fever survivors cross-react with recombinant proteins representing Lassa viruses of divergent lineages.
    Heinrich ML; Boisen ML; Nelson DKS; Bush DJ; Cross RW; Koval AP; Hoffmann AR; Beddingfield BJ; Hastie KM; Rowland MM; Aimukanova I; Koval S; Lathigra R; Borisevich V; Momoh M; Sandi JD; Goba A; Odia L; Baimba F; Aiyepada JO; Ebo B; Eromon P; Ugwu C; Folarin O; Olumade T; Onyechi MN; Etafo J; Adeyemi R; Ella EE; Aminu M; Gomerep SS; Eke MA; Ogunsanya O; Akpede GO; Asogun DO; Okogbenin SA; Okokhere PO; Holst J; Shaffer JG; Schieffelin JS; Geisbert TW; Saphire EO; Happi CT; Grant DS; Garry RF; Branco LM
    Sci Rep; 2020 Sep; 10(1):16030. PubMed ID: 32994446
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inter-Lineage Variation of Lassa Virus Glycoprotein Epitopes: A Challenge to Lassa Virus Vaccine Development.
    Ibukun FI
    Viruses; 2020 Mar; 12(4):. PubMed ID: 32244402
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death.
    Cross RW; Xu R; Matassov D; Hamm S; Latham TE; Gerardi CS; Nowak RM; Geisbert JB; Ota-Setlik A; Agans KN; Luckay A; Witko SE; Soukieh L; Deer DJ; Mire CE; Feldmann H; Happi C; Fenton KA; Eldridge JH; Geisbert TW
    J Clin Invest; 2020 Jan; 130(1):539-551. PubMed ID: 31820871
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Convergent Structures Illuminate Features for Germline Antibody Binding and Pan-Lassa Virus Neutralization.
    Hastie KM; Cross RW; Harkins SS; Zandonatti MA; Koval AP; Heinrich ML; Rowland MM; Robinson JE; Geisbert TW; Garry RF; Branco LM; Saphire EO
    Cell; 2019 Aug; 178(4):1004-1015.e14. PubMed ID: 31398326
    [TBL] [Abstract][Full Text] [Related]  

  • 37. VaxCelerate II: rapid development of a self-assembling vaccine for Lassa fever.
    Leblanc P; Moise L; Luza C; Chantaralawan K; Lezeau L; Yuan J; Field M; Richer D; Boyle C; Martin WD; Fishman JB; Berg EA; Baker D; Zeigler B; Mais DE; Taylor W; Coleman R; Warren HS; Gelfand JA; De Groot AS; Brauns T; Poznansky MC
    Hum Vaccin Immunother; 2014; 10(10):3022-38. PubMed ID: 25483693
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HLA-C-restricted viral epitopes are associated with an escape mechanism from KIR2DL2
    Wauquier N; Petitdemange C; Tarantino N; Maucourant C; Coomber M; Lungay V; Bangura J; Debré P; Vieillard V
    EBioMedicine; 2019 Feb; 40():605-613. PubMed ID: 30711514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset.
    Safronetz D; Rosenke K; Westover JB; Martellaro C; Okumura A; Furuta Y; Geisbert J; Saturday G; Komeno T; Geisbert TW; Feldmann H; Gowen BB
    Sci Rep; 2015 Oct; 5():14775. PubMed ID: 26456301
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A multivalent vaccination strategy for the prevention of Old World arenavirus infection in humans.
    Botten J; Whitton JL; Barrowman P; Sidney J; Whitmire JK; Alexander J; Kotturi MF; Sette A; Buchmeier MJ
    J Virol; 2010 Oct; 84(19):9947-56. PubMed ID: 20668086
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.